Sarepta Therapeutics (SRPT)
(Real Time Quote from BATS)
$114.06 USD
-9.40 (-7.61%)
Updated May 28, 2024 12:22 PM ET
3-Hold of 5 3
D Value D Growth A Momentum D VGM
Price, Consensus and EPS Surprise
SRPT 114.06 -9.40(-7.61%)
Will SRPT be a Portfolio Killer in May?
Zacks Investment Research is releasing its prediction for SRPT based on the 1-3 month trading system that more than doubles the S&P 500.
About Price, Consensus and EPS Surprise
The Price, Consensus and EPS Surprise chart displays the company's stock price along with the consensus estimate and the EPS surprise. Zacks tracks individual sell-side analyst estimates and creates a consensus EPS estimates. The consensus estimate is the average of all the current estimates made available by brokerage analysts. Consensus estimates are more advantageous because they reduce the risk of any single analyst making an incorrect forecast. ZACKS CONSENSUS ESTIMATE = THE AVERAGE OF ALL CURRENT EPS ESTIMATES. EPS Surprise is the difference (expressed as a percentage) between the actual reported quarterly earnings per share (EPS) vs the estimated quarterly EPS. A company that reports $1.10 in actual quarterly EPS vs. $1.00 in estimated quarterly EPS would show a 10% positive EPS surprise. ((Actual EPS - Estimated EPS) / absolute Estimated EPS) *100 = EPS Surprise %.
Zacks News for SRPT
Implied Volatility Surging for Sarepta (SRPT) Stock Options
Dyne (DYN) Soars 28% on New Data From Muscle Disease Studies
SRPT: What are Zacks experts saying now?
Zacks Private Portfolio Services
Sarepta (SRPT) Q1 Earnings Beat Estimates, Revenues Up Y/Y
Sarepta Therapeutics (SRPT) Q1 Earnings: Taking a Look at Key Metrics Versus Estimates
Sarepta Therapeutics (SRPT) Q1 Earnings and Revenues Beat Estimates
Other News for SRPT
What You Missed On Wall Street This Morning
Sarepta Therapeutics Breaks Below 200-Day Moving Average - Notable for SRPT
Airbnb upgraded, Southwest downgraded: Wall Street's top analyst calls
RBC downgrades Sarepta on growing expectations into Elevidys decision
RBC Capital gets more bearish on Sarepta, downgrades shares